Gala Early Feasibility Study of RheOx

NAUnknownINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

July 6, 2018

Primary Completion Date

January 30, 2021

Study Completion Date

December 30, 2024

Conditions
Chronic BronchitisCopd Bronchitis
Interventions
DEVICE

RheOx

RheOx is a device-based, energy delivery system that delivers energy to ablate soft tissue such as the airway epithelium and sub-mucosal tissue layers. The energy is delivered via a proprietary catheter through the bronchoscope.

Trial Locations (8)

15213

University of Pittsburgh Medical Center, Pittsburgh

19140

Temple University School of Medicine, Philadelphia

21237

MedStar Health, Baltimore

32224

Mayo Clinic Florida, Jacksonville

35249

University of Alabama Lung Health Center, Birmingham

52242

University of Iowa, Iowa City

60637

University of Chicago, Chicago

02215

Beth Israel Deaconess, Boston

Sponsors
All Listed Sponsors
lead

Gala Therapeutics, Inc.

INDUSTRY